{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:25:21Z","timestamp":1790828721124,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To evaluate the use of direct hemoperfusion with polymyxin B-immobilized fiber (PMX-DHP) as adjunctive therapy during pediatric patients with septic shock.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Prospective observational study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Nine-bed PICUs at university referral hospital.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Children (30 d to 15 yr) with septic shock and Pediatric Logistic Organ Dysfunction (PELOD)-2 score greater than or equal to 10 or Pediatric Risk of Mortality (PRISM) 3 score greater than or equal to 15, who were also receiving at least one inotrope.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTION:<\/jats:title>\n            <jats:p>Patients received 2\u20134 hour treatment with PMX-DHP 20R column on 2 consecutive days.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>We enrolled six children aged 21\u2013167 months old (median, 99-mo old), with a body weight of 10\u201350\u2009kg (median, 28\u2009kg). All six patients had both PELOD-2 greater than or equal to 10 and PRISM-3 greater than or equal to 15, required invasive mechanical ventilation, and received standard treatment for septic shock before enrollment. We observed significant improvement in PELOD-2 score from baseline to 72 hours after the start of PMX-DHP (mean [95% CI] from 14.3 [12.2\u201316.5] to 6.0 [0.3\u201311.7]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.006). The vasoactive inotropic score (VIS) and lactate concentration also significantly decreased from baseline to 72 hours (VIS, 60 mmol\/L [25\u201395 mmol\/L] to 4.0 mmol\/L [44.1\u201312 mmol\/L]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.003; lactate, 2.4 mmol\/L [1.0\u20133.8 mmol\/L] to 1.0 mmol\/L [0.5\u20131.5 mmol\/L]; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.01). Five of six patients survived. There was no device-related adverse event in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>In this case series of treatment with PMX-DHP as adjunctive therapy in children with refractory septic shock and high baseline severity, we have shown that patient recruitment is feasible. We have also found that clinical hemodynamic and severity of illness scores at 72 hours may be potential end points for testing in future randomized controlled trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pcc.0000000000002969","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T15:08:12Z","timestamp":1654873692000},"page":"e386-e391","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Polymyxin B Hemoperfusion in Pediatric Septic Shock: Single-Center Observational Case Series"],"prefix":"10.1097","volume":"23","author":[{"given":"Patcharin","family":"Saetang","sequence":"first","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujipat","family":"Samransamruajkit","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanokwan","family":"Singjam","sequence":"additional","affiliation":[{"name":"Division of Pediatric Critical Care, Pediatric Intensive Care Unit, King Chulalongkorn Memorial Hospital, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawatchai","family":"Deekajorndech","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"issue":"Suppl 4","key":"R1-20250502","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1186\/cc3748","article-title":"Microvascular dysfunction as a cause of organ dysfunction in severe sepsis.","volume":"9","author":"Vincent","year":"2005","journal-title":"Crit Care"},{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature01326","article-title":"The immunopathogenesis of sepsis.","volume":"420","author":"Cohen","year":"2002","journal-title":"Nature"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/cc9411","article-title":"Clinical review: Blood purification for sepsis.","volume":"15","author":"Rimmel\u00e9","year":"2011","journal-title":"Crit Care"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1473-3099(10)70220-6","article-title":"Endotoxin removal devices for the treatment of sepsis and septic shock.","volume":"11","author":"Davies","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"613","DOI":"10.4103\/0972-5229.167044","article-title":"Continuous renal replacement therapy in children with severe sepsis and multiorgan dysfunction - a pilot study on timing of initiation.","volume":"19","author":"Gulla","year":"2015","journal-title":"Indian J Crit Care Med"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1744-9987.1998.tb00066.x","article-title":"Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: Designing and antiendotoxin efficacy in the clinical application.","volume":"2","author":"Shoji","year":"1998","journal-title":"Ther Apher"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000187169","article-title":"The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin B-immobilized fiber column in septic patients with colorectal perforation.","volume":"42","author":"Shimizu","year":"2009","journal-title":"Eur Surg Res"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/cc13912","article-title":"Polymyxin B hemoperfusion: A mechanistic perspective.","volume":"18","author":"Ronco","year":"2014","journal-title":"Crit Care"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/jama.2009.856","article-title":"Early use of polymyxin B hemoperfusion in abdominal septic shock: The EUPHAS randomized controlled trial.","volume":"301","author":"Cruz","year":"2009","journal-title":"JAMA"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2018.14618","article-title":"Targeted polymyxin-B hemoperfusion for the treatment of endotoxemia and septic shock: A multicenter randomized controlled trial (EUPHRATES).","volume":"320","author":"Dellinger","year":"2018","journal-title":"JAMA"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1007\/s00134-018-5463-7","article-title":"Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: A post hoc analysis of the EUPHRATES trial.","volume":"44","author":"Klein","year":"2018","journal-title":"Intensive Care Med"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00134-012-2769-8","article-title":"Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock 2012.","volume":"39","author":"Dellinger","year":"2013","journal-title":"Intensive Care Med"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00467-003-1342-7","article-title":"Renal replacement therapy for acute renal failure in children: European guidelines.","volume":"19","author":"Strazdins","year":"2004","journal-title":"Pediatr Nephrol"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1097\/CCM.0b013e31828a2bbd","article-title":"PELOD-2: An update of the Pediatric Logistic Organ Dysfunction Score.","volume":"41","author":"Leteurtre","year":"2013","journal-title":"Crit Care Med"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00003246-199605000-00004","article-title":"PRISM III: An updated pediatric risk of mortality score.","volume":"24","author":"Pollack","year":"1996","journal-title":"Crit Care Med"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/PCC.0000000000001191","article-title":"Validation of the vasoactive-inotropic score in pediatric sepsis.","volume":"18","author":"McIntosh","year":"2017","journal-title":"Pediatr Crit Care Med"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1111\/ped.13002","article-title":"Efficacy of polymyxin B-immobilized fiber column direct hemoperfusion for non-endotoxin-associated severe septic shock.","volume":"58","author":"Saito","year":"2016","journal-title":"Pediatr Int"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4266\/acc.2017.00528","article-title":"A successful application of adult polymyxin B-immobilized fiber column hemoperfusion to a neonate with septic shock.","volume":"34","author":"Kim","year":"2019","journal-title":"Acute Crit Care"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"49","DOI":"10.20517\/2574-1209.2017.11","article-title":"Blood purification in intensive care patients with multiple organ dysfunction syndrome and sepsis after cardiac surgery.","volume":"1","author":"Yaroustovsky","year":"2017","journal-title":"Vessel Plus"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/PCC.0000000000002132","article-title":"Clinical effects and outcomes after polymyxin B-immobilized fiber column direct hemoperfusion treatment for septic shock in preterm neonates.","volume":"21","author":"Nishizaki","year":"2020","journal-title":"Pediatr Crit Care Med"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/ped.13006","article-title":"Polymyxin B-immobilized fiber column direct hemoperfusion and continuous hemodiafiltration in premature neonates with systemic inflammatory response syndrome.","volume":"58","author":"Maede","year":"2016","journal-title":"Pediatr Int"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00134-010-1830-8","article-title":"Hypercytokinemia with 2009 pandemic H1N1 (pH1N1) influenza successfully treated with polymyxin B-immobilized fiber column hemoperfusion.","volume":"36","author":"Takeda","year":"2010","journal-title":"Intensive Care Med"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jca.10019","article-title":"Direct hemoperfusion using a polymyxin B immobilized column improves acute respiratory distress syndrome.","volume":"17","author":"Tsushima","year":"2002","journal-title":"J Clin Apher"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1378\/chest.12-0994","article-title":"Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion.","volume":"143","author":"Sato","year":"2013","journal-title":"Chest"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2169\/internalmedicine.53.2687","article-title":"Effects of direct hemoperfusion with polymyxin B-immobilized fiber on rapidly progressive interstitial lung diseases.","volume":"53","author":"Takada","year":"2014","journal-title":"Intern Med"},{"key":"R26-20250502","first-page":"135","article-title":"Pediatric Logistic Organ Dysfunction-2 (Pelod-2) score as a model for predicting mortality in pediatric burn injury.","volume":"32","author":"Dewi","year":"2019","journal-title":"Ann Burns Fire Disasters"}],"container-title":["Pediatric Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000002969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T17:24:20Z","timestamp":1746206660000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PCC.0000000000002969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/pcc.0000000000002969","relation":{},"ISSN":["1529-7535"],"issn-type":[{"value":"1529-7535","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}